SOURCE: CLX Investment Company, Inc.

November 29, 2006 14:15 ET

CLX Investment Company Reports on Zonda, Inc.'s Exhibit at MEDICA Trade Event

TEMECULA, CA -- (MARKET WIRE) -- November 29, 2006 -- CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund, today reported on portfolio investment Zonda, Incorporated's successful appearance at MEDICA -- the 38th World Forum for Medicine, billed as the world's largest medical trade fair. The annual appearance at MEDICA was used to spotlight Zonda's HandiLab line of innovative medical diagnostic tests and as a center point for meetings with major European distributors and potential worldwide distributors of Zonda products.

The MEDICA event was held November 15-18, 2006 in Düsseldorf, Germany. Zonda's booth was located in the U.S. Pavilion located in Building 3 at the Messe Düsseldorf Exhibition Center. Over 137,000 registered visitors attended the show, which featured leading medical companies from around the world.

Prior to MEDICA, Zonda management traveled to the United Kingdom and Norway to meet with distributors of the HandiLab-C.

Laurie J. Oleksiewicz, president of Zonda, Incorporated, commented, "There was considerable interest in our exhibit at MEDICA this year, with very good feedback from current and potential distributors. We had numerous scheduled meetings during the event, and we made nearly 100 new contacts in the medical industry. We will be following up with the new contacts made at MEDICA, so we can explore potential business relationships with these companies."

"Recent orders for Zonda's HandiLab-C test for chlamydia from the European market have been strong and include the largest single order ever placed," stated chief executive officer Robert McCoy. "We are pleased with how far this portfolio company has progressed since we first made our investment, and Zonda continues to increase its presence in Europe with new distribution agreements for the HandiLab-C. MEDICA allowed Zonda management to meet with current distributors, as well as introduce its products to potential new distributors for Europe and other worldwide markets."

The HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use, which signifies that it complies with the relevant health, safety, environmental protection requirements in Europe and can therefore be legally placed on the market. Zonda's gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About Zonda, Incorporated

Zonda, Inc. (, in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company ( holds a 31% equity interest in Zonda, Inc. ( CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact